Suchergebnisse - (Standardsuche:issn:"1756-8919" OR issn:"1756-8927")

PubPharm (421)

51

PROTAC cell permeability and oral bioavailability : a journey into uncharted territory

enthalten in: Future medicinal chemistry | 2022

von Poongavanam, V. | Kihlberg, J.

52

Comprehensive analysis of R-groups in medicinal chemistry

enthalten in: Future medicinal chemistry | 2022

von Bajorath, J.

53

Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy

enthalten in: Future medicinal chemistry | 2022

von Mallareddy, J. | Singh, S. | Boghean, L. | +1

54

Challenges and opportunities for in vivo PROTAC delivery

enthalten in: Future medicinal chemistry | 2022

von Benowitz, A. | Scott-Stevens, P. | Harling, J.

55

Targeting STK33 : from inhibition to degradation

enthalten in: Future medicinal chemistry | 2022

von Zhong, S. | Wayne, J.

56

Mitigating inflammation using advanced drug delivery by targeting TNF-α in lung diseases

enthalten in: Future medicinal chemistry | 2022

von Das, S. | Singh, S. | Verma, P. | +3

57

Protein-protein interactions by influenza polymerase subunits as drug targets

enthalten in: Future medicinal chemistry | 2022

von Felicetti, T. | Massari, S.

58

Can dextran-based nanoparticles mitigate inflammatory lung diseases?

enthalten in: Future medicinal chemistry | 2021

von Prasher, P. | Sharma, M. | R Wich, P. | +4

59

Rifamycins : do not throw the baby out with the bathwater. Is rifampicin still an effective anti-tuberculosis drug?

enthalten in: Future medicinal chemistry | 2021

von Brucoli, F. | D McHugh, T.

60

Exploitation of a novel allosteric binding region in DNA gyrase and its implications for antibacterial drug discovery

enthalten in: Future medicinal chemistry | 2021

von M Orritt, K. | Maxwell, A. | Wg Fishwick, C. | +1